INSERM, UMR_S 1138, Cordeliers Research Center, Team "Cancer, immune control and escape", Paris, France.
University Paris Descartes Paris, Sorbonne Paris Cite, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.
Clin Cancer Res. 2017 Aug 1;23(15):4416-4428. doi: 10.1158/1078-0432.CCR-16-2848. Epub 2017 Feb 17.
The efficacy of PD-1 checkpoint blockade as adjuvant therapy in localized clear cell renal cell carcinoma (ccRCC) is currently unknown. The identification of tumor microenvironment (TME) prognostic biomarkers in this setting may help define which patients could benefit from checkpoint blockade and uncover new therapeutic targets. We performed multiparametric flow cytometric immunophenotypic analysis of T cells isolated from tumor tissue [tumor-infiltrating lymphocytes (TIL)], adjacent non-malignant renal tissue [renal-infiltrating lymphocytes (RIL)], and peripheral blood lymphocytes (PBL), in a cohort of patients ( = 40) with localized ccRCC. Immunophenotypic data were integrated with prognostic and histopathologic variables, T-cell receptor (TCR) repertoire analysis of sorted CD8PD-1 TILs, tumor mRNA expression, and digital quantitative immunohistochemistry. On the basis of TIL phenotypic characterization, we identified three dominant immune profiles in localized ccRCC: (i) immune-regulated, characterized by polyclonal/poorly cytotoxic CD8PD-1Tim-3Lag-3 TILs and CD4ICOS cells with a Treg phenotype (CD25CD127Foxp3/HeliosGITR), that developed in inflamed tumors with prominent infiltrations by dysfunctional dendritic cells and high PD-L1 expression; (ii) immune-activated, enriched in oligoclonal/cytotoxic CD8PD-1Tim-3 TILs, that represented 22% of the tumors; and (iii) immune-silent, enriched in TILs exhibiting RIL-like phenotype, that represented 56% of patients in the cohort. Only immune-regulated tumors displayed aggressive histologic features, high risk of disease progression in the year following nephrectomy, and a CD8PD-1Tim-3 and CD4ICOS PBL phenotypic signature. In localized ccRCC, the infiltration with CD8PD-1Tim-3Lag-3 exhausted TILs and ICOS Treg identifies the patients with deleterious prognosis who could benefit from adjuvant therapy with TME-modulating agents and checkpoint blockade. This work also provides PBL phenotypic markers that could allow their identification. .
PD-1 检查点阻断作为局部透明细胞肾细胞癌 (ccRCC) 的辅助治疗的疗效目前尚不清楚。在这种情况下,识别肿瘤微环境 (TME) 的预后生物标志物可能有助于确定哪些患者可能受益于检查点阻断,并发现新的治疗靶点。我们对一组局部 ccRCC 患者的肿瘤组织 [肿瘤浸润淋巴细胞 (TIL)]、相邻非恶性肾组织 [肾浸润淋巴细胞 (RIL)] 和外周血淋巴细胞 (PBL) 中的 T 细胞进行了多参数流式细胞仪免疫表型分析(= 40)。免疫表型数据与预后和组织病理学变量、分选的 CD8PD-1TILs 的 T 细胞受体 (TCR) 谱分析、肿瘤 mRNA 表达和数字定量免疫组织化学相结合。基于 TIL 表型特征,我们在局部 ccRCC 中鉴定了三种主要的免疫特征:(i) 免疫调节型,其特征是多克隆/低细胞毒性 CD8PD-1Tim-3Lag-3TILs 和具有 Treg 表型的 CD4ICOS 细胞(CD25CD127Foxp3/HeliosGITR),在炎症性肿瘤中发展,这些肿瘤具有明显的功能失调树突状细胞浸润和高 PD-L1 表达;(ii) 免疫激活型,富含寡克隆/细胞毒性 CD8PD-1Tim-3TILs,占肿瘤的 22%;(iii) 免疫沉默型,富含表现出 RIL 样表型的 TILs,在队列中的 56%患者中。只有免疫调节型肿瘤表现出侵袭性组织学特征、肾切除术一年后疾病进展的高风险,以及 CD8PD-1Tim-3 和 CD4ICOS PBL 表型特征。在局部 ccRCC 中,CD8PD-1Tim-3Lag-3 耗尽的 TILs 和 ICOS Treg 的浸润可识别出预后不良的患者,他们可能受益于 TME 调节药物和检查点阻断的辅助治疗。这项工作还提供了 PBL 表型标志物,可以识别它们。